Skip to content

A Study to Compare Magnesium Sulphate Gel With and Without Iontophoresis for Jaw Muscle Pain in TMJ Disorders

Comparative Evaluation of Topical Magnesium Sulphate Gel With and Without Iontophoresis in Management of Masseter Myalgia in Temporomandibular Joint Disorders A Randomized Controlled Study - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103262
Enrollment
62
Registered
2026-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M266- Temporomandibular joint disorders

Interventions

Intervention1: Topical Magnesium Sulphate Gel With Iontophoresis: Topical magnesium sulphate gel iontophoresis will be performed twice weekly for four weeks. Control Intervention1: Topical Magnesium S

Sponsors

DR Swathy M S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants with TMDs having unilateral or bilateral masseter myalgia based on DC/TMD criteria.1( Annexure III) 2. Participants 18 to 60 years of age of either gender .

Exclusion criteria

Exclusion criteria: F. EXCLUSION CRITERIA: 1. The presence of congenital abnormalities affecting TMJ and associated structures. 2. The presence of systemic diseases like cervicalgia or rheumatological diseases like rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, viral myalgia etc. 3. Any history of trauma ,cervical spine or TMJ surgery 4. Patients who are undergoing orthodontic treatment or recent extractions . 5. Patients currently under treatment for temporomandibular disorders. 6. Patients with history of radiation treatment to head and neck region. 7. Individuals with pacemakers and metal implants. 8. Pregnant and lactating women. 9. Patients who have limited mouth opening due to non-TMD causes such as odontogenic infections,OSMF,fractures etc. 10. Patients under medications which can affect muscle activity like muscle relaxants, antidepressants, etc 11. Patients with history of skin allergy/allergic to medications used in present treatment . 12. Patients who had any infection, lesion or trauma in the region of electrode placement

Design outcomes

Primary

MeasureTime frame
VAS score, maximum mouth opening (MMO), and quality of lifeTimepoint: At baseline and after end of treatment of 4 weeks

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Swathy M S

Government dental college and research institute bangalore

drsumannag99@yahoo.com09980839659

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026